UBS Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22M | Sell |
657,699
-175,041
| -21% | -$4.35M | ﹤0.01% | 2584 |
|
|
2026
Q1 | $17.4M | Buy |
832,740
+163,929
| +25% | +$3.69M | ﹤0.01% | 2738 |
|
|
2025
Q4 | $15.4M | Buy |
668,811
+121,786
| +22% | +$4M | ﹤0.01% | 2835 |
|
|
2025
Q3 | $16.5M | Buy |
547,025
+106,593
| +24% | +$3.2M | ﹤0.01% | 2779 |
|
|
2025
Q2 | $16M | Sell |
440,432
-29,050
| -6% | -$1.05M | ﹤0.01% | 2608 |
|
|
2025
Q1 | $17M | Buy |
469,482
+143,831
| +44% | +$5.98M | ﹤0.01% | 2511 |
|
|
2024
Q4 | $13.7M | Buy |
325,651
+232,582
| +250% | +$11.5M | ﹤0.01% | 2727 |
|
|
2024
Q3 | $5.17M | Sell |
93,069
-102,822
| -52% | -$5.24M | ﹤0.01% | 3028 |
|
|
2024
Q2 | $8.05M | Buy |
195,891
+26,728
| +16% | +$1.14M | ﹤0.01% | 2415 |
|
|
2024
Q1 | $7.9M | Buy |
169,163
+111,342
| +193% | +$5.25M | ﹤0.01% | 2491 |
|
|
2023
Q4 | $2.77M | Buy |
57,821
+11,429
| +25% | +$443K | ﹤0.01% | 3467 |
|
|
2023
Q3 | $1.65M | Sell |
46,392
-17,078
| -27% | -$677K | ﹤0.01% | 3628 |
|
|
2023
Q2 | $2.93M | Sell |
63,470
-11,510
| -15% | -$534K | ﹤0.01% | 3132 |
|
|
2023
Q1 | $3.01M | Sell |
74,980
-90,118
| -55% | -$3.87M | ﹤0.01% | 2999 |
|
|
2022
Q4 | $7.65M | Buy |
165,098
+135,455
| +457% | +$5.33M | ﹤0.01% | 2116 |
|
|
2022
Q3 | $1.23M | Sell |
29,643
-17,506
| -37% | -$900K | ﹤0.01% | 3580 |
|
|
2022
Q2 | $2.81M | Sell |
47,149
-45,188
| -49% | -$2.78M | ﹤0.01% | 2852 |
|
|
2022
Q1 | $6.71M | Buy |
92,337
+28,959
| +46% | +$2.01M | ﹤0.01% | 2265 |
|
|
2021
Q4 | $5.33M | Buy |
63,378
+7,193
| +13% | +$585K | ﹤0.01% | 2750 |
|
|
2021
Q3 | $5.07M | Buy |
56,185
+30,559
| +119% | +$2.76M | ﹤0.01% | 2660 |
|
|
2021
Q2 | $2.44M | Sell |
25,626
-24,003
| -48% | -$2.5M | ﹤0.01% | 3395 |
|
|
2021
Q1 | $5.65M | Buy |
49,629
+22,002
| +80% | +$3M | ﹤0.01% | 2465 |
|
|
2020
Q4 | $3.83M | Buy |
27,627
+1,470
| +6% | +$174K | ﹤0.01% | 2729 |
|
|
2020
Q3 | $2.15M | Sell |
26,157
-5,562
| -18% | -$461K | ﹤0.01% | 2975 |
|
|
2020
Q2 | $2.48M | Sell |
31,719
-99,111
| -76% | -$6.56M | ﹤0.01% | 2675 |
|
|
2020
Q1 | $5.81M | Buy |
130,830
+48,730
| +59% | +$2.53M | ﹤0.01% | 1803 |
|
|
2019
Q4 | $3.51M | Sell |
82,100
-82,148
| -50% | -$3.39M | ﹤0.01% | 2951 |
|
|
2019
Q3 | $7.03M | Buy |
164,248
+124,167
| +310% | +$6.75M | ﹤0.01% | 2073 |
|
|
2019
Q2 | $2.54M | Buy |
40,081
+11,717
| +41% | +$746K | ﹤0.01% | 2926 |
|
|
2019
Q1 | $1.97M | Sell |
28,364
-121,450
| -81% | -$6.94M | ﹤0.01% | 3006 |
|
|
2018
Q4 | $6.51M | Buy |
149,814
+108,380
| +262% | +$5.92M | ﹤0.01% | 1927 |
|
|
2018
Q3 | $3.16M | Buy |
41,434
+13,200
| +47% | +$1.07M | ﹤0.01% | 2776 |
|
|
2018
Q2 | $2.17M | Sell |
28,234
-85,918
| -75% | -$5.55M | ﹤0.01% | 3086 |
|
|
2018
Q1 | $5.82M | Buy |
114,152
+90,294
| +378% | +$4.55M | ﹤0.01% | 2159 |
|
|
2017
Q4 | $1.11M | Sell |
23,858
-11,562
| -33% | -$567K | ﹤0.01% | 3703 |
|
|
2017
Q3 | $1.89M | Buy |
35,420
+18,098
| +104% | +$1.07M | ﹤0.01% | 3178 |
|
|
2017
Q2 | $1.07M | Buy |
17,322
+7,608
| +78% | +$458K | ﹤0.01% | 3556 |
|
|
2017
Q1 | $658K | Sell |
9,714
-36,956
| -79% | -$2.82M | ﹤0.01% | 3853 |
|
|
2016
Q4 | $3.28M | Buy |
46,670
+16,636
| +55% | +$1.18M | ﹤0.01% | 2453 |
|
|
2016
Q3 | $2.13M | Buy |
30,034
+3,120
| +12% | +$199K | ﹤0.01% | 2781 |
|
|
2016
Q2 | $1.32M | Buy |
26,914
+13,633
| +103% | +$882K | ﹤0.01% | 3141 |
|
|
2016
Q1 | $841K | Sell |
13,281
-3,845
| -22% | -$252K | ﹤0.01% | 3399 |
|
|
2015
Q4 | $1.92M | Buy |
17,126
+6,989
| +69% | +$699K | ﹤0.01% | 2830 |
|
|
2015
Q3 | $977K | Sell |
10,137
-18,425
| -65% | -$2.11M | ﹤0.01% | 3370 |
|
|
2015
Q2 | $2.92M | Buy |
28,562
+18,807
| +193% | +$1.46M | ﹤0.01% | 2609 |
|
|
2015
Q1 | $606K | Buy |
9,755
+203
| +2% | +$11.3K | ﹤0.01% | 3982 |
|
|
2014
Q4 | $419K | Buy |
+9,552
| New | +$438K | ﹤0.01% | 4351 |
|
Other funds holding RARE
RI
FCM
UBS Group's RARE Position: Q2 2026 in Review
UBS Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 21% in Q2 2026, selling an estimated $4.35M and leaving 657,699 shares worth $22M. The position accounts for ﹤0.01% of the portfolio, ranked #2584.
UBS Group first reported a position in RARE in Q4 2014 and has held it in 47 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- UBS Group held 657,699 shares of Ultragenyx Pharmaceutical worth $22M as of Q2 2026.
- UBS Group sold 175,041 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $4.35M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2584 holding.
- UBS Group first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 47 quarters since.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.